首页> 外文期刊>Nature >Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells
【24h】

Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells

机译:人类BCR-ABL1淋巴细胞白血病起始细胞的进化

获取原文
获取原文并翻译 | 示例
       

摘要

Many tumours are composed of genetically diverse cells; however, little is known about how diversity evolves or the impact that diversity has on functional properties. Here, using xenografting and DNA copy number alteration (CNA) profiling of human BCR-ABL1 lymphoblastic leukaemia, we demonstrate that genetic diversity occurs in functionally defined leukaemia-initiating cells and that many diagnostic patient samples contain multiple genetically distinct leukaemia-initiating cell subclones. Reconstructing the subclonal genetic ancestry of several samples by CNA profiling demonstrated a branching multi-clonal evolution model of leukaemogenesis, rather than linear succession. For some patient samples, the predominant diagnostic clone repopulated xenografts, whereas in others it was outcompeted by minor subclones. Reconstitution with the predominant diagnosis clone was associated with more aggressive growth properties in xenografts, deletion of CDKN2A and CDKN2B, and a trend towards poorer patient outcome. Our findings link clonal diversity with leukaemia-initiating-cell function and underscore the importance of developing therapies that eradicate all intratumoral subclones.
机译:许多肿瘤由遗传上不同的细胞组成。然而,人们对多样性如何演变或多样性对功能特性的影响知之甚少。在这里,使用人类BCR-ABL1淋巴细胞白血病的异种移植和DNA拷贝数改变(CNA)分析,我们证明了遗传多样性发生在功能定义的白血病起始细胞中,并且许多诊断患者样品包含多个遗传上不同的白血病起始细胞亚克隆。通过CNA分析重建几个样品的亚克隆遗传血统,证明了白细胞生成的分支多克隆进化模型,而不是线性继承。对于某些患者样品,主要的诊断克隆会重新填充异种移植物,而在另一些患者中,次要的亚克隆却无法与之竞争。用主要的诊断克隆重建与异种移植物中更具侵略性的生长特性,CDKN2A和CDKN2B的缺失以及患者预后不良的趋势相关。我们的发现将克隆多样性与白血病起始细胞功能联系起来,并强调了开发根除所有肿瘤内亚克隆的疗法的重要性。

著录项

  • 来源
    《Nature》 |2011年第7330期|p.362-367|共6页
  • 作者单位

    Division of Stem Cell and Developmental Biology, Campbell Family Institute for Cancer Research/Ontario Cancer Institute, Toronto, Ontario M5G 1L7, Canada,Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1L7, Canada;

    Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA;

    Division of Stem Cell and Developmental Biology, Campbell Family Institute for Cancer Research/Ontario Cancer Institute, Toronto, Ontario M5G 1L7, Canada,Department of Medical Oncology and Hematology, Princess Margaret Hospital, and Department of Medicine, University of Toronto, Toronto, Ontario M5G 2M9, Canada;

    Division of Stem Cell and Developmental Biology, Campbell Family Institute for Cancer Research/Ontario Cancer Institute, Toronto, Ontario M5G 1L7, Canada;

    Division of Stem Cell and Developmental Biology, Campbell Family Institute for Cancer Research/Ontario Cancer Institute, Toronto, Ontario M5G 1L7, Canada,Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1L7, Canada;

    Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA;

    Hartwell Center for Bioinformatics and Biotechnology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA;

    Department of Medical Oncology and Hematology, Princess Margaret Hospital, and Department of Medicine, University of Toronto, Toronto, Ontario M5G 2M9, Canada;

    Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA;

    Division of Stem Cell and Developmental Biology, Campbell Family Institute for Cancer Research/Ontario Cancer Institute, Toronto, Ontario M5G 1L7, Canada,Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1L7, Canada;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:54:28

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号